Comments
Loading...
Treace Medical Concepts Analyst Ratings and Price Targets | NASDAQ:TMCI | Benzinga
Treace Medical Concepts Inc has a consensus price target of $10.81 based on the ratings of 9 analysts. The high is $25 issued by Stephens & Co. on September 12, 2023. The low is $7 issued by UBS on August 7, 2024. The 3 most-recent analyst ratings were released by Truist Securities on April 11, 2025, March 13, 2025, and March 3, 2025, respectively. With an average price target of $9.17 between Truist Securities, there's an implied 40.49% upside for Treace Medical Concepts Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Lake Street
JP Morgan
Stifel
UBS
1calculated from analyst ratings
Analyst Ratings for Treace Medical Concepts
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/11/2025 | Buy Now | 22.61% | Truist Securities | Richard Newitter74% | $9.5 → $8 | Maintains | Hold | Get Alert |
| 03/13/2025 | Buy Now | 45.59% | Truist Securities | Richard Newitter74% | $10 → $9.5 | Maintains | Hold | Get Alert |
| 03/03/2025 | Buy Now | 53.26% | Truist Securities | Richard Newitter74% | $8.4 → $10 | Maintains | Hold | Get Alert |
| 12/31/2024 | Buy Now | 122.22% | Lake Street | Ben Haynor36% | → $14.5 | Initiates | → Buy | Get Alert |
| 12/18/2024 | Buy Now | 28.74% | Truist Securities | Richard Newitter74% | $7 → $8.4 | Maintains | Hold | Get Alert |
| 12/17/2024 | Buy Now | 22.61% | JP Morgan | Lilia-Celine Lozada29% | → $8 | Assumes | → Neutral | Get Alert |
| 11/06/2024 | Buy Now | 22.61% | Stifel | Rick Wise73% | $7 → $8 | Maintains | Hold | Get Alert |
| 10/14/2024 | Buy Now | -8.05% | Truist Securities | Richard Newitter74% | $7.5 → $6 | Maintains | Hold | Get Alert |
| 08/07/2024 | Buy Now | 7.28% | UBS | Danielle Antalffy58% | $6.5 → $7 | Maintains | Neutral | Get Alert |
| 08/07/2024 | Buy Now | 14.94% | Truist Securities | Richard Newitter74% | $9 → $7.5 | Maintains | Hold | Get Alert |
| 07/16/2024 | Buy Now | 37.93% | Truist Securities | Richard Newitter74% | $7 → $9 | Maintains | Hold | Get Alert |
| 07/15/2024 | Buy Now | 22.61% | Morgan Stanley | Drew Ranieri45% | $5.5 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/16/2024 | Buy Now | -0.38% | UBS | Danielle Antalffy58% | $16 → $6.5 | Downgrade | Buy → Neutral | Get Alert |
| 05/08/2024 | Buy Now | -15.71% | Morgan Stanley | Drew Ranieri45% | $15 → $5.5 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 145.21% | UBS | Danielle Antalffy58% | $17 → $16 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 7.28% | Truist Securities | Richard Newitter74% | $17 → $7 | Downgrade | Buy → Hold | Get Alert |
| 05/08/2024 | Buy Now | 22.61% | JP Morgan | Robbie Marcus66% | $15 → $8 | Downgrade | Overweight → Neutral | Get Alert |
| 05/08/2024 | Buy Now | — | BTIG | Ryan Zimmerman71% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/08/2024 | Buy Now | -8.05% | Stifel | Rick Wise73% | $15 → $6 | Downgrade | Buy → Hold | Get Alert |
| 12/22/2023 | Buy Now | 145.21% | Truist Securities | Richard Newitter74% | $12 → $16 | Maintains | Buy | Get Alert |
| 11/13/2023 | Buy Now | 114.56% | Morgan Stanley | Drew Ranieri45% | $30 → $14 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 68.58% | Stifel | Rick Wise73% | $28 → $11 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 83.91% | Truist Securities | Richard Newitter74% | $17 → $12 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 329.12% | Stifel | Rick Wise73% | → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/29/2023 | Buy Now | 267.82% | UBS | Danielle Antalffy58% | → $24 | Initiates | → Buy | Get Alert |
| 09/12/2023 | Buy Now | 283.14% | Stephens & Co. | George Sellers38% | → $25 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/28/2023 | Buy Now | 313.79% | BTIG | Ryan Zimmerman71% | $32 → $27.5 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 283.14% | Stephens & Co. | George Sellers38% | $27 → $25 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 359.77% | Truist Securities | Richard Newitter74% | $33 → $30 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 313.79% | Stephens & Co. | George Sellers38% | → $27 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 05/01/2023 | Buy Now | 405.75% | Truist Securities | Richard Newitter74% | → $33 | Initiates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 390.42% | BTIG | Ryan Zimmerman71% | $29 → $32 | Maintains | Buy | Get Alert |
| 04/11/2023 | Buy Now | 298.47% | Stephens & Co. | George Sellers38% | → $26 | Initiates | → Equal-Weight | Get Alert |
| 03/08/2023 | Buy Now | 359.77% | Morgan Stanley | Drew Ranieri45% | $28 → $30 | Maintains | Overweight | Get Alert |
| 10/11/2022 | Buy Now | 329.12% | Morgan Stanley | Drew Ranieri45% | $23 → $28 | Maintains | Overweight | Get Alert |
| 09/21/2022 | Buy Now | 329.12% | BTIG | Ryan Zimmerman71% | $23 → $28 | Maintains | Buy | Get Alert |
| 09/21/2022 | Buy Now | 313.79% | Stifel | Rick Wise73% | $24 → $27 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 252.49% | Morgan Stanley | Drew Ranieri45% | $22 → $23 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | 221.84% | Stifel | Rick Wise73% | $32 → $21 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 237.16% | Morgan Stanley | Drew Ranieri45% | $26 → $22 | Maintains | Overweight | Get Alert |
| 05/12/2022 | Buy Now | 237.16% | BTIG | Ryan Zimmerman71% | → $22 | Initiates | → Buy | Get Alert |
| 05/09/2022 | Buy Now | 298.47% | Morgan Stanley | Drew Ranieri45% | $28 → $26 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Treace Medical Concepts (TMCI) stock?
The latest price target for Treace Medical Concepts (NASDAQ:TMCI) was reported by Truist Securities on April 11, 2025. The analyst firm set a price target for $8.00 expecting TMCI to rise to within 12 months (a possible 22.61% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Treace Medical Concepts (TMCI)?
The latest analyst rating for Treace Medical Concepts (NASDAQ:TMCI) was provided by Truist Securities, and Treace Medical Concepts maintained their hold rating.
When was the last upgrade for Treace Medical Concepts (TMCI)?
There is no last upgrade for Treace Medical Concepts
When was the last downgrade for Treace Medical Concepts (TMCI)?
The last downgrade for Treace Medical Concepts Inc happened on May 16, 2024 when UBS changed their price target from $16 to $6.5 for Treace Medical Concepts Inc.
When is the next analyst rating going to be posted or updated for Treace Medical Concepts (TMCI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Treace Medical Concepts, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Treace Medical Concepts was filed on April 11, 2025 so you should expect the next rating to be made available sometime around April 11, 2026.
Is the Analyst Rating Treace Medical Concepts (TMCI) correct?
While ratings are subjective and will change, the latest Treace Medical Concepts (TMCI) rating was a maintained with a price target of $9.50 to $8.00. The current price Treace Medical Concepts (TMCI) is trading at is $6.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
